Medpace (NASDAQ:MEDP) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Medpace (NASDAQ:MEDP) from a buy rating to a hold rating in a research note published on Saturday.

Several other equities research analysts also recently weighed in on MEDP. Robert W. Baird set a $613.00 price target on Medpace in a report on Friday, October 24th. Barclays upped their price target on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Truist Financial set a $555.00 price objective on Medpace in a report on Monday, October 27th. Mizuho boosted their price objective on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Finally, Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and lifted their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $490.82.

Medpace Stock Performance

Shares of MEDP opened at $571.53 on Friday. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $626.26. The firm has a 50-day simple moving average of $575.60 and a 200-day simple moving average of $475.06. The company has a market capitalization of $16.10 billion, a price-to-earnings ratio of 39.97, a price-to-earnings-growth ratio of 2.14 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter in the previous year, the firm posted $3.01 EPS. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts forecast that Medpace will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares in the company, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This represents a 58.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 387,925 shares of company stock valued at $233,386,647 over the last ninety days. Corporate insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Large investors have recently modified their holdings of the business. Fifth Third Wealth Advisors LLC boosted its holdings in Medpace by 2.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the last quarter. BOKF NA raised its position in shares of Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares in the last quarter. HighPoint Advisor Group LLC raised its position in shares of Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares in the last quarter. Portside Wealth Group LLC boosted its stake in shares of Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after buying an additional 27 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its position in shares of Medpace by 35.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after buying an additional 27 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.